Peer-reviewed veterinary case report
Bleomycin and cytosine arabinoside chemo for dogs with relapsed
By Batschinski, Karen et al.·Published in Journal of the American Animal Hospital Association·2018·From the Laboratory of Experimental and Comparative Oncology, Department of Pathology, School of Veterinary Medicine and Animal Sciences, University of São Paulo, Brazil, São Paulo, Brazil (K.B.); Department of Small Animal Clinical Sciences, Virginia–Maryland Regional College of Veterinary Medicine, Blacksburg, Virginia (N.D.); Oncology Department, VCA Veterinary Care Animal Hospital and Referral Center, Albuquerque, New Mexico (B.K.); and Oncology Department..., Brazil·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Combination of Bleomycin and Cytosine Arabinoside Chemotherapy for Relapsed Canine Lymphoma
- Species:
- dog
Plain-English summary
A group of dogs with relapsed lymphoma (a type of cancer) received a combination of two chemotherapy drugs, bleomycin and cytosine arabinoside, to see if it would help them after previous treatments failed. Out of 19 dogs treated, about 37% showed some improvement, but the average time before the cancer progressed again was just 15 days. Some dogs experienced serious side effects, including low platelet and white blood cell counts. Overall, this treatment had limited success as a rescue option for dogs that had already been through multiple rounds of chemotherapy.
People also search for: dog lymphoma treatment options · chemotherapy side effects in dogs · relapsed lymphoma in dogs
Abstract
ABSTRACT A retrospective study was performed to evaluate response rate, time to progression, and toxicity of a bleomycin and cytosine arabinoside (Bleo/Cytarabine) combination protocol for dogs with relapsed lymphoma (LSA). Dogs diagnosed with LSA and previously treated with chemotherapy were included in the study. A total of 20 dogs met the inclusion criteria, and 19 were evaluable for response. Bleomycin was administered subcutaneously on days 1 and 8 and cytosine arabinoside was administered subcutaneously on days 1–5 of a 21-day cycle. The median number of chemotherapy drugs given prior to the administration of Bleo/Cytarabine was 8.5. A total of 23 cycles of Bleo/Cytarabine were administered. The overall response rate was 36.8% (7 of 19 dogs had a partial response). The median time to progression was 15 days. Three dogs developed grade 3 thrombocytopenia and one dog had a grade 4 neutropenia. Bleo/Cytarabine had minor activity when used as a rescue therapy for pretreated LSA patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.5326/jaaha-ms-6617